Long-term effects of perindopril on metabolic parameters and the heart in the spontaneously hypertensive/NIH-corpulent rat with non-insulin- dependent diabetes mellitus and hypertension

Metabolism: Clinical and Experimental

Volumn 47, Issue 10, 1998, Pages 1199-1204

  Striffler, John S ^a   Bhathena, Sam J ^c   Michaelis IV, Otho E ^c   Campbell, Joaquin D ^c   Hansen, Carl T ^c   Scalbert, Elizabeth ^c   Thibault, Nancy ^c   Velasquez, Manuel T ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; PERINDOPRIL; TRIACYLGLYCEROL;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HEART WEIGHT; HYPERTENSION; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; MUSCLE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; SOLEUS MUSCLE;

EID: 0031751841     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90323-7     Document Type: Article

References (55)

1. Fuller JH: Epidemiology of hypertension with diabetes mellitus. Hypertension 7:11113-11117, 1985 (suppl)
2. Panzram G: Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30:123-131, 1987
3. Kannel WB, Wilson PWF, Zhang TJ: The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 121:1268-1273, 1991
4. Olefsky JM, Kolterman OG, Scarlett JA: Insulin action and resistance in obesity and non-insulin dependent type II diabetes mellitus. Am J Physiol 243:E15-E30, 1982
5. DeFronzo RA, Ferrannini E: The pathogenesis of non-insulin-dependent diabetes: An update. Medicine (Baltimore) 61:125-140, 1982
6. Modan M, Halkin H, Almog S, et al: Hyperinsulinemia: A link between hypertension, obesity, and glucose intolerance. J Clin Invest 75:809-817, 1985
7. Ferrannini E, Buzzigoli G, Bonadonna R, et al: Insulin resistance in essential hypertension. N Engl J Med 317:350-357, 1987
8. Pyorala K: Relationships of glucose intolerance and plasma insulin to the incidence of coronary heart disease: Results from two population studies in Finland. Diabetes Care 2:131-141, 1979
9. Fuller JH, Shipley MJ, Rose G, et al: Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall Study. Lancet 1:1373-1376, 1980
10. Eschwege P, Richard JL, Thibault N, et al: Coronary heart disease mortality in relation with diabetes, blood glucose, and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res 15:41-46, 1985 (suppl)
11. Zavaroni I, Bonora E, Pagliara M, et al: Risk factors for coronary artery disease with hyperinsulinemia and glucose tolerance. N Engl J Med 320:702-706, 1989
12. Inchiostro S, Bertoli G, Zanette G, et al: Evidence of higher insulin resistance in NIDDM patients with ischemic heart disease. Diabetologia 37:597-603, 1994
13. Jauch KW, Hartl W, Guenther B, et al: Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 17:448-454, 1987
14. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321:868-873, 1989
15. +2 antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. Diabetes Care 14:911-914, 1991
16. Moore MP, Elliott TW, Nichols MG: Hormonal and metabolic effects of enalapril treatment in hypertensive subjects with NIDDM. Diabetes Care 11:397-401, 1988
17. Paolliso G, Gambardella A, Verza M, et al: ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 6:175-179, 1992
18. Santoro D, Natali A, Palombo C, et al: Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension 20:181-191, 1992
19. Donnelly R: Angiotensin-converting enzyme inhibitors and insulin sensitivity: Metabolic effects in hypertension, diabetes, and heart failure. J Cardiovasc Pharmacol 20:S38-S44, 1992 (suppl 11)
20. Corcoran JS, Perkins JE, Hoffbrand BI, et al: Treating hypertension in non-insulin-dependent diabetes: A comparison of atenolol, nifedipine, and captopril combined with bendrofluazide. Diabet Med 4:164-168, 1987
21. Bilo HJG, Westerman RF, Nicolas-Mercus AM, et al: Effect of enalapril with and without hydrochlorothiazide in hypertensive patients with non-insulin-dependent diabetes mellitus. Diabetes Res 9:21-25, 1988
22. Prince MJ, Stuart CA, Padia M, et al: Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patient: Enalapril for hypertensive diabetics. Arch Intern Med 148:2363-2368, 1988
23. Seefeldt T, Orskov L, Mengel A, et al: Lack of effect of angiotensin-converting enzyme (ACE)-inhibitors on glucose metabo-lism in type 1 diabetes. Diabet Med 7:700-704, 1990
24. Reneland R, Andersson PE, Haenni A, et al: Metabolic effects of long-term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: Relationship to angiotensin-converting enzyme inhibition. Eur J Clin Pharmacol 46:431-436, 1994
25. Haenni A, Andersson PE, Lind L, et al: Electrolyte changes and metabolic effects of lisinopril/bendrofluazide treatment. Am J Hypertens 7:615-622, 1994
26. Andersson PE, Lithell H: Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men: Relationship to changes in skeletal muscle blood flow. Am J Hypertens 9:323-333, 1996
27. Shionoiri H, Miyakawa T, Takasaki I, et al: Glucose tolerance during chronic captopril therapy in patients with essential hypertension. J Cardiovasc Pharmacol 9:160-164, 1987
28. Shionoiri H, Sugimoto K, Minamisawa K, et al: Glucose and lipid metabolism during long-term treatment with cilazapril in hypertensive patients with or without impaired glucose metabolism. J Cardiovasc Pharmacol 15:933-938, 1990
29. Ludvik B, Kueenburg E, Brunnbauer M, et al: The effects of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with essential hypertension. J Cardiovasc Pharmacol 18:157-159, 1991
30. Michaelis OE IV, Ellwood KC, Judge JM, et al: Effect of dietary sucrose on the SHR/N-corpulent rat: A new model for insulin-independent diabetes. Am J Clin Nutr 39:612-618, 1984
31. Michaelis OE IV, Patrick DH, Hansen CT, et al: Spontaneous hypertensive/NIH-corpulent rat. Animal model for insulin-independent diabetes mellitus (type II). Am J Pathol 123:398-400, 1986
32. MacFadyen RJ, Lees KR, Reid JL: Perindopril. A review of its pharmacokinetics and clinical pharmacology. Drugs 39:49-63, 1990 (suppl 1)
33. Bunag RD: Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol 34:279-282, 1973
34. Carswell N, Michaelis OE IV, Prather E: Effect of acarbose (BAY-g-5421) on expression of noninsulin-dependent diabetes mellitus in sucrose-fed SHR/N-corpulent rats. J Nutr 119:388-394, 1989
35. Cuendet GS, Loten EG, Jeanrenaud B, et al: Decreased basal, noninsulin-stimulated glucose uptake and metabolism by skeletal soleus muscle isolated from obese-hyperglycemic (ob/ob) mice. J Clin Invest 58:1078-1088, 1976
36. Bondar RJ, Mead DC: Evaluation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides in the hexokinase method for determining glucose in the serum. Clin Chem 20:586-590, 1974
37. Mondon CE, Reaven GM: Evidence of abnormalities of insulin metabolism in rats with spontaneous hypertension. Metabolism 37:303-305, 1988
38. Reaven GM, Chang H, Hoffman BB, et al: Resistance to insulin-stimulated glucose uptake in adipocytes isolated from spontaneously hypertensive rats. Diabetes 38:1155-1160, 1989
39. Bak JF, Gerdes LU, Sorensen NS, et al: Effect of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients. Am J Med 92:69S-72S, 1992 (suppl 4B)
40. Baba T, Neugebauer S: The link between insulin resistance and hypertension: Effects of antihypertensive and antihyperlipidaemic drugs on insulin sensitivity. Drugs 47:383-404, 1994
41. Gall M-A, Rossing P, Skott P, et al: Placebo-controlled comparison of captopril, metoprolol, and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension. Am J Hypertens 5:257-265, 1992
42. Lillioja S, Young AA, Culber CL, et al: Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest 80:415-424, 1987
43. Laakso M, Edelman SV, Brechtel G, et al: Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 85:1844-1852, 1990
44. Tomiyama H, Kushior T, Abeta H, et al: Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitors. Hypertension 23:450-455, 1994
45. Meyer HU, Curchod B, Maeder E, et al: Modifications of glucose storage in nonobese diabetics, measured by continuous indirect calorimetry. Diabetes 29:752-756, 1980
46. Young AA, Bogardus C, Wolfe-Lopez D, et al: Muscle glycogen synthesis and disposition of infused glucose in humans with reduced rates of insulin-mediated carbohydrate storage. Diabetes 37:303-308, 1988
47. Leighton B, Cooper GJS: Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 335:632-635, 1988
48. Kreutter DK, Orena SJ, Torchia AJ, et al: Amylin and CGRP induce insulin resistance via a receptor distinct from cAMP-coupled CGRP receptor. Am J Physiol 264:E606-E613, 1993 (suppl)
49. Henriksen EJ, Jacob S: Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism 44:267-272, 1995
50. Rosenthal T, Erlich Y, Rosenmann E, et al: Effects of enalapril, losartan, and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat. Hypertension 29:1260-1264, 1997
51. Vander AJ, Geelhoed GW: Inhibition of renin secretion by angiotensin II. Proc Soc Exp Biol Med 120:399-403, 1965
52. Kostis JB, Raia JJ Jr, DeFelice EA, et al: Comparative clinical pharmacology of ACE inhibitors, in Kostis JB, DeFelice EA (eds): Angiotensin Converting Enzyme Inhibitors. New York, NY, Liss, 1987, pp 19-54
53. Dunn FG, Oigman W, Ventura HO: Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 53:105-108, 1984
54. Frohlich ED: Pathophysiological considerations in left ventricular hypertrophy. J Clin Hypertens 3:54-65, 1987
55. Devereux RB, Pickering TG, Cody RS: Relation of renin-angiotensin system activity to left ventricular hypertrophy and function in experimental and human hypertension. J Clin Hypertens 3:87-103, 1987